Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 9Small Cell Lung Carcinoma 4Respiratory Tract Diseases 3NSCLC 3Lung Diseases 3Thoracic Neoplasms 2Extensive Stage Small Cell Lung Cancer 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Small Cell Lung Cancer Extensive Stage 1Respiratory Tract Neoplasms 1Radiation Pneumonitis 1Pleural Effusion, Malignant 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms by Site 1Neoplasms 1Multiple Primary Lung Cancer 1Esophageal Neoplasms 1CRC 1Brain Neoplasms 1Advanced NSCLC 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 2Carboplatin 2toripalimab 1camrelizumab 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non Squamous Non Small Cell Lung Cancer × camrelizumab × Thoracic × Clear all
NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

CrystalGenomics, Inc.

Phase 2 Recruiting
60 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡